About Vepdegestrant Vepdegestrant is an investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) estrogen receptor degrader. Vepdegestrant is being developed as a potential ...

Gan & Lee Pharmaceuticals Co. Ltd. has discovered proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) binding agent coupled to interleukin-1 receptor-associated kinase 4 ...

Cyclin-dependent kinase 6 (CDK6) plays a crucial role in the G1 phase to S phase transition of the cell cycle. Aberrant activation of CDK6 has been linked with the development and progression of ...

Arvinas, in collaboration with Pfizer, has announced new drug application (NDA) acceptance for vepdegestrant from the US Food ...

The FDA accepts a new drug application for vepdegestrant, a promising oral PROTAC developed by Arvinas and Pfizer, signaling potential breakthroughs in treatment.

Study participants were randomly assigned to receive either oral vepdegestrant (n=313) or intramuscular fulvestrant (n=311). The primary endpoint was progression free survival (PFS) among all patients ...

Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural ...

The U.S. Food and Drug Administration is currently reviewing a New Drug Application for vepdegestrant, a pioneering PROTAC® (PROteolysis TArgeting Chimera, a type of TPD) molecule targeting ...

Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer – – Presented ...

Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor, which could generate $1.3 billion-plus for the San Diego biotech.